Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Heparin-induced Thrombocytopenia - Market Insight, Epidemiology, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's offering.
Heparin-induced thrombocytopenia is a serious immune-mediated response to heparin administration. Managing HIT involves stopping heparin and deploying alternative anticoagulants like argatroban and bivalirudin. Direct oral anticoagulants (DOACs) are emerging as alternatives, providing convenience over traditional warfarin.
Several companies such as Veralox Therapeutics, Sandoz, and Fresenius Kabi are key players in the HIT treatment market. In 2023, the US had around a 50% market share within the 7MM. Germany led the EU4 and UK with 40% of the market, while Japan contributed around USD 3 million.
Key Highlights
- The heparin-induced thrombocytopenia (HIT) market size in the 7MM is anticipated to reach approximately USD 128 million in 2023.
- HIT is marked by a sudden decline in platelet count 5-14 days after starting heparin therapy. This condition is triggered by antibodies against the platelet factor 4 (PF4)-heparin complex.
- The diagnostic protocol for HIT includes a mix of clinical evaluation, laboratory testing, and the 4Ts scoring method, with testing focused on platelet count and anti-PF4/heparin antibodies.
- Treatment involves discontinuing heparin and commencing alternative non-heparin anticoagulants like direct thrombin inhibitors (e.g., argatroban) or factor Xa inhibitors (e.g., fondaparinux).
- In 2023, Argatroban captured the largest market share, contributing USD 62 million to the HIT market.
- VLX-1005 (Veralox Therapeutics) is under investigation as a HIT treatment, receiving FDA fast-track designation following positive Phase I results in June 2022.
- The United States represents about 51% of the HIT market in terms of diagnosed incident cases, with approximately 220,800 incidents noted in 2023.
- In the EU4 and UK, Germany leads in incident cases, followed by France, making up 23% of the total cases.
Emerging and Established Therapies
The HIT market sees promising developments with drugs like ANGIOMAX (bivalirudin) from Sandoz and Argatroban from Fresenius Kabi. Meanwhile, VLX-1005 from Veralox Therapeutics is a potential game-changer, undergoing Phase II trials aimed at disrupting HIT's landscape. Innovative therapies targeting unique pathways provide a significant improvement in management and outcomes for HIT patients.
An in-depth understanding of these dynamics, together with market projections to 2034, reveals an optimistic growth outlook, influenced by new therapies and rising healthcare expenditures.
Market Insights and Future Outlook
Continued innovation and the introduction of new anticoagulants will likely shape the future of HIT treatment, addressing long-standing unmet medical needs. The market will be further informed by extensive research and expert opinions, aiming at evolving therapies that cater to patient preference and reduce complication rates.
As the HIT market progresses, a focus on affordability and market access will be crucial, ensuring patients receive the most effective and advanced treatments available.
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Heparin-induced Thrombocytopenia (HIT) Market Overview at a Glance
4. Executive Summary of Heparin-induced Thrombocytopenia (HIT)
5. Key Events
6. Disease Background and Overview
6.1. Heparin as a Medication and Different Forms of Heparin
6.2. Types of HIT
6.3. Signs and Symptoms
6.4. Risk Factors
6.5. Pathophysiology of Heparin-induced Thrombocytopenia (HIT)
6.6. Clinical Presentation and Complications
6.7. Diagnosis
6.8. Diagnostic Guidelines
7. Treatment of Heparin-induced Thrombocytopenia
7.1. Alternative Anticoagulation
7.2. Alternatives and Adjuvants to Coagulation
7.3. Treatment Guidelines
8. Methodology
9. Heparin-induced Thrombocytopenia Epidemiology and Patient Population
9.1. Key Findings
9.2. Assumptions and Rationale
9.3. Total Incident Cases in the 7MM
9.4. The United States
9.5. EU4 and the UK
9.6. Japan
10. Heparin-induced Thrombocytopenia Patient Journey
11. Heparin-induced Thrombocytopenia Marketed Therapies
12. Heparin-induced Thrombocytopenia Emerging Therapies
13. Heparin-induced Thrombocytopenia (HIT): Seven Major Market Analysis
14. KOL Views
15. SWOT Analysis
16. Heparin-induced Thrombocytopenia Unmet Needs
17. Market Access and Reimbursement
For more information about this report visit https://www.researchandmarkets.com/r/pvn5fp
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
